Lantern Pharma (LTRN) Common Equity (2019 - 2026)

Lantern Pharma (LTRN) has reported Common Equity for 8 consecutive years, with -$3.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 125.69% year-over-year to -$3.2 million; the trailing twelve-month figure through Jun 2026 stood at -$3.2 million (down 125.69% YoY), and the FY2025 full-year result was $6.5 million, down 69.16% from the prior year.
• Common Equity declined to -$3.2 million in Q2 2026 per LTRN's latest filing, from $3.4 million in the prior quarter.
• Across five years, Common Equity topped out at $65.3 million in Q1 2022 and bottomed at -$3.2 million in Q2 2026.
• Historically, Common Equity has averaged $32.7 million across 5 years, with a median of $33.3 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Common Equity decreased 19.51% in 2023, then slumped 125.69% in 2026.
• Over 5 years, Common Equity stood at $56.0 million in 2022, then slipped by 27.0% to $40.9 million in 2023, then slumped by 48.21% to $21.2 million in 2024, then slumped by 69.16% to $6.5 million in 2025, then sank by 149.24% to -$3.2 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$3.2 million, $3.4 million, and $6.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.